Request Demo
Legacy Pharma Inc. SEZC Announces the Acquisition of InterMune, Inc. and the U.S. Rights to Esbriet® from Genentech a Member of the Roche Group
AcquisitionDrug Approval
George Town, Cayman Islands, February 06, 2025 --(PR.com)-- Legacy Pharma Inc. SEZC (“Legacy Pharma” or the “Company”), a specialty pharmaceutical company, announced the completion of the acquisition of InterMune, Inc. (“InterMune”) and the intellectual property rights to Esbriet® (pirfenidone) in the United States from Genentech, a member of the Roche Group. This strategic acquisition underscores Legacy Pharma's commitment to expanding its portfolio of high-quality pharmaceutical products and enhancing patient access to innovative treatments. Esbriet®, a medication used to treat idiopathic pulmonary fibrosis (IPF), has shown significant promise in improving the lives of patients with this chronic and life-threatening lung disease. With this acquisition, Legacy Pharma aims to ensure the continued availability and distribution of Esbriet® to patients across the United States. Genentech will continue to provide access to Esbriet® in the United States until the completion of the business transfer. Furthermore, Roche will retain commercial rights in all other territories. "We are excited to acquire InterMune and add Esbriet® to our portfolio of essential medications," said Mark Thompson, CEO of Legacy Pharma. "This acquisition aligns with our mission to provide patients with access to innovative and life-changing treatments." Legacy Pharma Inc. SEZC is dedicated to maintaining the highest standards of quality and customer service. The Company's acquisition of InterMune and certain U.S. intellectual property rights to Esbriet® is a testament to its ongoing commitment to expanding its portfolio of legacy pharmaceutical products and strengthening its collaboration with key partners in the industry, such as Genentech.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!